Strides Shasun today said it
has received an approval from the US
health regulator for Ranitidine tablets used for
treating intestinal and stomach ulcers and
gastroesophageal reflux disease.
In a BSE filing, Strides BSE 0.12 % Shasun said "it has received approval from the US Food and Drug Administration (USFDA) for Ranitidine tablets USP, 150 mg and 300 mg". The company will manufacture the product at its Cuddalore and Pondicherry facilities.
In a BSE filing, Strides BSE 0.12 % Shasun said "it has received approval from the US Food and Drug Administration (USFDA) for Ranitidine tablets USP, 150 mg and 300 mg". The company will manufacture the product at its Cuddalore and Pondicherry facilities.
No comments:
Post a Comment